Page 6 - டிஷ் புற்றுநோய் நிறுவனம் இல் ஏற்ற சினை News Today : Breaking News, Live Updates & Top Stories | Vimarsana

 E-Mail New York, NY (April 10, 2021) - A personalized cancer vaccine developed with the help of a Mount Sinai computational platform raised no safety concerns and showed potential benefit in patients with different cancers, including lung and bladder, that have a high risk of recurrence, according to results from an investigator-initiated phase I clinical trial presented during the virtual American Association for Cancer Research (AACR) Annual Meeting 2021, held April 10-15. While immunotherapy has revolutionized the treatment of cancer, the vast majority of patients do not experience a significant clinical response with such treatments, said study author Thomas Marron, MD, PhD, Assistant Director for Early Phase and Immunotherapy Trials at The Tisch Cancer Institute and Assistant Professor of Medicine (Hematology and Medical Oncology) at the Icahn School of Medicine at Mount Sinai. Cancer vaccines, which typically combine tumor-specific targets that the immune system can lear

New yorkUnited statesLong islandNina bhardwajThomas marronHealth systemTisch cancer instituteTisch cancer institute at mount sinaiCancer researchAmerican association for cancer researchIcahn school of medicine at mount sinaiImmunotherapy programParker institute for cancer immunotherapyMount sinai health systemIcahn school of medicineMount sinai